文献速递泌尿生殖腹部MR

MRI检测的结外延伸作为前列腺癌侵袭性的标志物

MRI-detected extranodal extension as a marker of prostate cancer aggressiveness.
PubMed 文献 · Eur Radiol · 2025-04-05

这项回顾性单中心研究纳入461例前列腺癌患者,分为无淋巴结受累组、有淋巴结受累无结外延伸组、有淋巴结受累伴结外延伸组,由两名放射科医生评估MRI上的结外延伸和PI-RADS。结外延伸患病率为4.1%,其Kappa系数为0.75;Cox模型显示结外延伸与特异性生存率(HR 8.50)和无进展生存率(HR 8.18)相关。作者认为MRI检测的结外延伸是独立预后标志物,但需进一步前瞻性多机构研究验证。

要点

  • MRI检测的结外延伸患病率低(4.1%),但重复性较好(Kappa 0.75)。
  • 结外延伸与特异性生存率(HR 8.50)和无进展生存率(HR 8.18)相关。
  • PI-RADS的重复性Kappa系数为0.48(95% CI 0.14-1.0)。

核心结论

  • MRI检测的结外延伸虽患病率低,但可预测前列腺癌的特异性生存率和无进展生存率,支持其作为独立预后标志物。

研究设计与样本

  • 回顾性单中心研究,纳入2013年1月至2017年12月经3-T MRI检查确诊的前列腺癌患者461例,分三组:无淋巴结受累组410例、有淋巴结受累无结外延伸组32例、有淋巴结受累伴结外延伸组19例;由两名经验丰富的放射科医生评估原发灶特征、淋巴结受累和结外延伸。

关键影像表现/征象

  • MRI评估原发灶特征、淋巴结受累及结外延伸。
  • 结外延伸的Kappa系数为0.75(95% CI 0.56-0.90),PI-RADS的Kappa系数为0.48(95% CI 0.14-1.0)。

诊断标准与关键数值

  • 结外延伸患病率为4.1%。
  • 结外延伸与特异性生存率相关:HR 8.50(95% CI 1.76-40.98,p < 0.01)。
  • PSA与特异性生存率相关:HR 1.009(95% CI 1.003-1.015,p < 0.01)。
  • 结外延伸与无进展生存率相关:HR 8.18(95% CI 2.34-28.58,p < 0.01)。
  • 淋巴结受累与无进展生存率相关:HR 5.99(95% CI 1.97-18.17,p < 0.01)。

临床应用与阅片要点

  • 作者认为MRI检测的结外延伸是一种可重复的影像特征,可能作为侵袭性前列腺癌的无创生物标志物。
  • 作者指出结外延伸与较差的无进展生存率和特异性生存率相关,可为患者管理提供预后信息。

局限性

  • 原文指出需要进一步的前瞻性、多机构研究来验证这些结果。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

英文原文(摘要)· 点击展开

OBJECTIVE: Extranodal extension (ENE) is a histological marker of aggressiveness for various cancers. We evaluated if clinical ENE, detected by Magnetic Resonance Imaging, can also serve as a biological marker of Prostate Cancer (PCa) aggressiveness.

MATERIALS AND METHODS: This retrospective, single-center study analyzed patients diagnosed with PCa and had MRI on a 3-T scanner from January 2013 to December 2017. After exclusions, 461 patients were included and divided into: Group 1, no lymph node involvement (LNI), Group 2 (LNI without ENE), and Group 3 (LNI and ENE). Two experienced radiologists assessed the MRI scans for primary lesion characteristics, LNI and ENE. Reproducibility assessment was calculated for ENE and PI-RADS. Clinical outcomes, including Overall Survival (OS), Specific Survival Rate (SSR), and Progression-Free Survival (PFS), were analyzed.

RESULTS: Group 1 included 410 patients, Group 2, 32 patients, and Group 3, 19 patients. The prevalence of ENE was 4.1%. Significant differences between groups were observed for age, PSA, dPSA, ISUP scores, clinical risk stratification, and staging (all p < 0.01). The Kappa coefficient for ENE was 0.75 (95% CI: 0.56-0.90), and 0.48 (0.14-1.0) for PI-RADS. Cox proportional hazards model showed PSA (HR: 1.009; 95% CI = 1.003-1.015, p < 0.01) and ENE (HR: 8.50; 1.76-40.98, p < 0.01) were associated with SSR, and both ENE (HR: 8.18; 2.34-28.58, p < 0.01) and LNI (HR: 5.99, 1.97-18.17, p < 0.01) were linked to poor PFS.

CONCLUSION: MRI-detected ENE, despite low prevalence, is a predictor of SSR and PFS in PCa. These findings support ENE as an independent prognostic marker. Further prospective, multi-institutional studies are required to validate these results.

KEY POINTS: Question Pathological extranodal extension (pENE) has been described as a marker of worrisome prognosis in prostate cancer (PCa), but clinical ENE has not been evaluated as a marker of prognosis in PCa. Findings MRI-detected clinical ENE, had a low prevalence in our cohort (4.1%), but it was a predictor of specific survival rate and progression-free survival. Clinical relevance MRI-detected clinical ENE, a reproducible imaging feature, may serve as a non-invasive biomarker for aggressive prostate cancer. It correlates with poorer progression-free survival and specific survival rates, offering valuable prognostic insights for patient management.

来源:Eur Radiol,查看原文。版权归原作者所有。

引用

  1. Naves AA, Gouvea GL, Machado CVB, et al. MRI-detected extranodal extension as a marker of prostate cancer aggressiveness. Eur Radiol. 2025. PMID: 40185926. doi:10.1007/s00330-025-11532-1

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。